Current Symptomatic and Disease-Modifying Treatments in Multiple System Atrophy.

Area of Science:

• Neuroscience
• Neuropathology
• Clinical Pharmacology

Background:

• Multiple system atrophy (MSA) is a rare, severe, rapidly progressive neurodegenerative disorder and an atypical parkinsonian syndrome.
• Characterized by parkinsonism, cerebellar ataxia, autonomic failure, and poor L-Dopa response, MSA has a mean life expectancy of 6-9 years post-diagnosis.
• The primary pathological hallmark is oligodendroglial cytoplasmic inclusions containing alpha-synuclein, classifying MSA as a synucleinopathy, alongside myelin and neuronal loss and glial activation.

Purpose of the Study:

• To summarize current symptomatic treatment strategies for MSA.
• To critically review potential cellular targets and disease-modifying approaches for MSA.
• To explore novel therapeutic avenues including targeting alpha-synuclein pathology, neuroinflammation, and neuronal loss.

Main Methods:

• Review of current clinical trials and pharmacological targets for MSA.
• Analysis of pathological hallmarks and pathomechanisms of MSA.
• Evaluation of single compound trials and the potential for combined therapeutic approaches.

Main Results:

• Current clinical trials primarily target key MSA symptoms: parkinsonism, cerebellar ataxia, and autonomic failure.
• Investigated disease-modifying approaches include targeting alpha-synuclein pathology, intervening in neuroinflammation, and addressing neuronal loss.
• Existing single compound trials aim to interfere with distinct pathogenetic steps in MSA.

Conclusions:

• Limited symptomatic treatments are available for MSA, with no current disease-modifying therapies.
• A combined therapeutic approach targeting multiple pathogenetic pathways may be necessary to slow the rapid progression of MSA.
• Further research into novel pharmacological targets and combined strategies is crucial for developing effective disease-modifying treatments for MSA.